Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 15;11(1):182.
doi: 10.3390/vaccines11010182.

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme

Andrea Kanizsai  1 , Laszlo Zavori  2 , Tihamer Molnar  3 , Margit Tőkés-Füzesi  4 , Zoltan Szalai  5 , Janos Berecz  6 , Reka Varnai  7 , Zoltan Peterfi  8 , Attila Schwarcz  9 , Peter Csecsei  9
Affiliations

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme

Andrea Kanizsai et al. Vaccines (Basel). .

Abstract

Background: It is known that adverse reactions following SARS-CoV-2 vaccinations show a positive correlation with the subsequent antibody titer. However, it is not clear how the adverse reactions following the booster vaccination are related to the antibody levels that can be measured after a 3rd dose. The primary goal of this study was to investigate whether the adverse reactions following the booster vaccination show a correlation with subsequent antibody levels.

Methods: Adverse reactions occurring within 7 days after the 3rd vaccination were recorded and the anti-SARS-CoV-2 spike protein immunoglobulin (Ig) level in the venous blood was measured on post-vaccination 14th, 60th and 120th days.

Results: A total of 218 volunteers were included in the study.

Main findings: (i) The adverse reactions that appeared after the booster dose did not show a positive correlation with the subsequent antibody level, except a correlation in the case of fever; (ii) there were more symptomatic patients in the group receiving heterologous booster vaccine, (iii) fever after the 2nd dose was independently associated with a reduction in the likelihood of COVID-19 positivity after the booster dose.

Conclusion: No adverse reactions, but fever showed a correlation with the antibody level after the booster SARS-CoV-2 vaccine.

Keywords: SARS-CoV-2; adverse reactions; booster vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Line diagram shows the change in the median anti SARS-CoV-2 IgG level 14, 60 and 120 days after heterologous (N = 17) or homologous (N = 201) booster vaccination. Day 0, immediately before 3rd dose.
Figure 2
Figure 2
Correlation of antibody titers with syptomatic status after the 2nd and 3rd vaccinations. (A) Antibody response of symptomatic versus non-symptomatic patients at 14 (N = 383), 60 (N = 320) and 120 (N = 268) days after the 2nd vaccination, (B) after the 3rd dose (N = 218 at all time points). Definition of a symptomatic individual: A local or systemic adverse reaction occurring within 7 days after vaccination. Statistical analysis was performed using Mann–Whitney-U test in each group, respectively. NS, non-significant; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. * indicates p < 0.05.
See this image and copyright information in PMC

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Dighriri I.M., Alhusayni K.M., Mobarki A.Y., Aljerary I.S., Alqurashi K.A., Aljuaid F.A., Alamri K.A., Mutwalli A.A., Maashi N.A., Aljohani A.M., et al. Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review. Cureus. 2022;14:e23526. doi: 10.7759/cureus.23526. - DOI - PMC - PubMed
    1. Menni C., May A., Polidori L., Louca P., Wolf J., Capdevila J., Hu C., Ourselin S., Steves C.J., Valdes A.M., et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 2022;22:1002–1010. doi: 10.1016/S1473-3099(22)00146-3. - DOI - PMC - PubMed
    1. Kanizsai A., Molnar T., Varnai R., Zavori L., Tőkés-Füzesi M., Szalai Z., Berecz J., Csecsei P. Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up. Vaccines. 2022;10:447. doi: 10.3390/vaccines10030447. - DOI - PMC - PubMed

LinkOut - more resources